Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma-comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off

Japanese Journal of Clinical Oncology

Volumn 44, Issue 3, 2014, Pages 270-277

  Kondo, Tsunenori ^a   Takagi, Toshio ^a   Kobayashi, Hirohito ^a   Iizuka, Junpei ^a   Nozaki, Taiji ^a   Hashimoto, Yasunobu ^a   Ikezawa, Eri ^a   Yoshida, Kazuhiko ^a   Omae, Kenji ^a   Tanabe, Kazunari ^a  

^a Tokyo Wom en's Medical University   (Japan)

Author keywords

Adverse drug event; Drug administration schedule; Drug tolerances; Renal cell carcinoma; Sunitinib

Indexed keywords

AMYLASE; SUNITINIB; TRIACYLGLYCEROL LIPASE; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; ILEUS; INTERSTITIAL PNEUMONIA; KIDNEY METASTASIS; LEUKOPENIA; LIVER DISEASE; LIVER DYSFUNCTION; LOSS OF APPETITE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ADVERSE DRUG REACTION; AGED; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG TOLERANCES; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADVERSE DRUG EVENT; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCES; RENAL CELL CARCINOMA; SUNITINIB;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899472740     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt232     Document Type: Article

References (19)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
2. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
3. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115-24.
6. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
7. Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. ASCO Meeting Abstracts 2012;30(15_suppl):CRA4502.
8. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes in metastatic renal cell carcinoma patients treated with alternative sunitinib schedules. J Urol 2013. doi: 10.1016/j.juro.2013.08.090.
9. Najjar YG, Elson P,Wood LS, Garcia JA, Dreicer R, Rini BI. Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. ASCO Meeting Abstracts 2013;31(6_suppl):406.
10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferonalpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
11. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
12. Pfizer Japan. Sutent Appropriate Use Guideline. Japan: Pfizer Japan; 2012.
13. Barrios CH, Hernandez-Barajas D, Brown MP, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012;118:1252-9.
14. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.
15. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30:1371-7.
16. Tomita Y, Shinohara N, Yuasa T, et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010;40:1166-72.
17. Yoo C, Kim JE, Lee JL, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010;40: 980-5.
18. Pfizer Japan. Postmarketing surveillance for Sutent 12.5 mg. Japan: Pfizer Japan; 2012.
19. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-63.